Serial assessment of myocardial properties using cyclic variation of integrated backscatter in an adriamycin-induced cardiomyopathy rat model.
Although adriamycin (Doxorubicin) is one of the most effective and useful antineoplastic agents for the treatment of a variety of malignancies, its repeated administration can induce irreversible myocardial damage and resultant heart failure. Currently, no marker to detect early cardiac damage is available. The purpose of this study was to investigate whether an assessment of the acoustic properties of the myocardium could enable the earlier detection of myocardial damage after adriamycin chemotherapy. Forty Wistar rats were treated with adriamycin (2 mg/kg, i.v.) once a week for 2, 4, 6 or 8 weeks consecutively. Left ventricular ejection fraction (LVEF) was calculated using M-mode echocardiography data. The magnitude of cardiac cycle dependent variation of integrated backscatter (CVIB) of the myocardium was measured in the mid segment of the septum and in the posterior wall of the left ventricle, using a real time two dimensional integrated backscatter imaging system. LVEF was significantly lower in the adriamycin-treated 8-week group than in the controls (75+/-9 vs 57+/-8%, p<0.05). Myocyte damage was only seen in the 8-week adriamycin-treated group. However, no significant changes of CVIB were observed between baseline or during follow-up in the ADR or control group. In conclusion, serial assessment of the acoustic properties of the myocardium may not be an optimal tool for the early detection of myocardial damage after doxorubicin chemotherapy in a rat model.
Ha
Jong-Won
JW
Cardiology Division, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea. jwha@yumc.yonsei.ac.kr
Kang
Seok-Min
SM
Pyun
Wook-Bum
WB
Lee
Joo-Yong
JY
Ahn
Mi-Young
MY
Kang
Woong-Chul
WC
Jeon
Tae Joo
TJ
Chung
Namsik
N
Lee
Jong-Doo
JD
Cho
Sang-Ho
SH
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000633:toxicity*; D004452:Echocardiography; D008297:Male; D051381:Rats; D017208:Rats, Wistar
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin
Eur J Nucl Med. 2000 Jun;27(6):686-93
10901455
Circulation. 1999 Oct 26;100(17):1770-6
10534463
Circulation. 1981 Oct;64(4):744-53
7273375
Circulation. 1987 Nov;76(5):1067-73
3311450
J Am Coll Cardiol. 1989 Jan;13(1):84-91
2642493
Circulation. 1989 Oct;80(4):925-34
2529060
Circulation. 1990 Mar;81(3):829-39
2306834
J Am Coll Cardiol. 1991 Apr;17(5):1085-90
1826118
J Am Coll Cardiol. 1992 May;19(6):1154-62
1564214
J Am Coll Cardiol. 1994 Aug;24(2):517-24
8034891
J Am Coll Cardiol. 1995 May;25(6):1408-15
7722141
Circulation. 1995 Sep 15;92(6):1452-7
7664426
Ann Intern Med. 1996 Jul 1;125(1):47-58
8644988
J Am Soc Echocardiogr. 1996 Jul-Aug;9(4):470-9
8827630
Circulation. 1997 Jan 7;95(1):140-50
8994429
Eur Heart J. 1997 Oct;18(10):1590-8
9347269
Am J Cardiol. 1998 Jan 1;81(1):68-74
9462609
Circulation. 1998 Feb 3;97(4):356-62
9468209
J Am Soc Echocardiogr. 2003 Aug;16(8):808-13
12878989